Shopping Cart
- Remove All
Your shopping cart is currently empty
TVB-3166 induces apoptosis and inhibits in-vivo xenograft tumor growth. TVB-3166 is a reversible and selective fatty acid synthase inhibitor (IC50s: 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $34 | In Stock | |
| 2 mg | $48 | In Stock | |
| 5 mg | $80 | In Stock | |
| 10 mg | $118 | In Stock | |
| 25 mg | $217 | In Stock | |
| 50 mg | $372 | In Stock | |
| 100 mg | $556 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock |
| Description | TVB-3166 induces apoptosis and inhibits in-vivo xenograft tumor growth. TVB-3166 is a reversible and selective fatty acid synthase inhibitor (IC50s: 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively). |
| Targets&IC50 | FASN:42 nM, Cellular palmitate synthesis:81 nM |
| In vitro | TVB-3166 (0.2 μM; 48 hours) inhibits β-catenin pathway signal transduction and transcriptional activity. TVB-3166 (0.02 or 0.20 μM; 7 days) suppresses palmitate synthesis and tumor cell viability in a dose-dependent manner. TVB-3166 (0.001-10 μM; 24 hours) induces cell death in CALU-6 non-small-cell lung tumor cells (cellular IC50: 0.10 μM) [1]. |
| In vivo | TVB-3166 (Oral gavage; 30-100 mg/kg/day) has the concentration is approximately 3-fold higher in plasma than the tumor. TVB-3166 (Oral gavage; 30-100 mg/kg/day) inhibits xenograft tumor growth. The 100 and 30 mg/kg groups had plasma and tumor concentrations of 7 and 2.9 μM, respectively [1]. |
| Molecular Weight | 384.47 |
| Formula | C24H24N4O |
| Cas No. | 1533438-83-3 |
| Smiles | CC=1C(=CC(C(=O)N2CC(C2)C3=CC=C(C#N)C=C3)=C(C)C1)C=4C(C)=C(C)NN4 |
| Relative Density. | 1.26 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (130.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.2 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.